Back to Search
Start Over
Oncopeptides completes enrollment in phase 3 study OCEAN to treat relapsed refractory MM
- Source :
- PharmaBiz. May 25, 2020
- Publication Year :
- 2020
-
Abstract
- Oncopeptides AB, a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, announced the successful completion of enrollment in the pivotal phase 3 study OCEAN for [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.624854761